BK vs EBS
The Bank of New York Mellon Corporation (BK) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
BK currently screens at market cap $94.14B and trailing P/E 17.0. EBS currently screens at market cap $416.4M.
Not investment advice. Open the BK and EBS stock pages for the full models.
Not investment advice.